Transfusion Medicine Reviews
Volume 23, Issue 1 , Pages 1-12 , January 2009

Cost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision Making

  • Brian Custer

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Brian Custer, MPH, PhD, Blood Systems Research Institute, 270 Masonic Ave, San Francisco, CA 94118.
    • ,
  • Jeffrey S. Hoch

References 

  1. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254–264
  2. Kleinman SH, Strong DM, Tegtmeier GG, et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion. 2005;45:1247–1257
  3. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion. 2007;47:2338–2347
  4. Reed W, Lee TH, Norris PJ, et al. Transfusion-associated microchimerism: A new complication of blood transfusions in severely injured patients. Seminrs Hematol. 2007;44:24–31
  5. Utter GH, Reed WF, Lee TH, et al. Transfusion-associated microchimerism. Vox Sang. 2007;93:188–195
  6. Pereira A. Determinants of costs in blood services: Blood transfusion from an economic perspective. Expert Rev Pharmacoecon Outcomes Res. 2002;2:10
  7. Ratko TA, Cummings JP, Matuszwewski KA, et al. Technology assessment: Leukocyte-reduced cellular blood components. Oak Brook, IL: University Health System Consortium; 2001;
  8. AuBuchon JP. Lessons learned from decision analysis. Transfusion. 1996;36:755–760
  9. AuBuchon JP. Cost-effectiveness of new blood safety technologies. Dev Biol Stand. 2000;102:211–215
  10. AuBuchon JP. Meeting transfusion safety expectations. Ann Intern Med. 2005;143:537–538
  11. Blumberg N. The costs and consequences of management fads and politically driven regulatory oversight. Arch Pathol Lab Med. 1999;123:580–584
  12. Pereira A. Cost-effectiveness analysis and the selection of blood products. Curr Opin Hematol. 2000;7:420–425
  13. Salmi LR, McClelland B, AuBuchon JP. The myth of the ultimate blood safety wall. Transfusion. 2001;41:716–717
  14. Davies L, Brown TJ, Haynes S, et al: Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: A systematic review and economic model. Health technology assessment (Winchester, England) 10:iii-iv, ix-x, 1-210, 2006.
  15. Duh MS, Weiner JR, White LA, et al. Management of anaemia: A critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. PharmacoEconomics. 2008;26:99–120
  16. Dzik S, Aubuchon J, Jeffries L, et al. Leukocyte reduction of blood components: Public policy and new technology. Transfus Med Rev. 2000;14:34–52
  17. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health technology assessment (Winchester, England). 11:1-202, iii-iv, 2007
  18. Blood counts. Washington, DC: America's Blood Centers; 2005;
  19. Amin M, Fergusson D, Aziz A, et al. The cost of allogeneic red blood cells—A systematic review. Transfus Med (Oxford, England). 2003;13:275–285
  20. Sullivan MT, Cotten R, Read EJ, et al. Blood collection and transfusion in the United States in 2001. Transfusion. 2007;47:385–394
  21. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45:141–148
  22. Sullivan MT, McCullough J, Schreiber GB, et al. Blood collection and transfusion in the United States in 1997. Transfusion. 2002;42:1253–1260
  23. Custer B. Economic analyses of blood safety and transfusion medicine interventions: A systematic review. Transfus Med Rev. 2004;18:127–143
  24. van Hulst M, de Wolf JT, Staginnus U, et al. Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sang. 2002;83:146–155
  25. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298:221–224
  26. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716–721
  27. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. PharmacoEconomics. 2003;21:149–157
  28. Orszag PR, Ellis P. Addressing rising health care costs—A view from the Congressional Budget Office. N Engl J Med. 2007;357:1885–1887
  29. Orszag PR, Ellis P. The challenge of rising health care costs—A view from the Congressional Budget Office. N Engl J Med. 2007;357:1793–1795
  30. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health. 2007;28:365–391
  31. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics. 2001;19:609–621
  32. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on good research practices—Budget impact analysis. Value Health. 2007;10:336–347
  33. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172–1177
  34. John-Baptiste A, Cook T, Straus S, et al. Decision analysis in aerospace medicine: Costs and benefits of a hyperbaric facility in space. Aviation, space, and environmental medicine 77: 434-442; discussion 442-443, 2006.
  35. Gold MR, Sofaer S, Siegelberg T. Medicare and cost-effectiveness analysis: Time to ask the taxpayers. Health Aff (Project Hope). 2007;26:1399–1406
  36. Organization WH . Threshold values for intervention cost-effectiveness by Region. 2000;
  37. Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: Why uncertainty about the outcome, estimate and willingness to pay matters. PharmacoEconomics. 2007;25:807–816
  38. Hoch JS, Smith MW. A guide to economic evaluation: Methods for cost-effectiveness analysis of person-level data. J Trauma Stress. 2006;19:787–797
  39. Custer B, Busch MP, Marfin AA, et al. The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med. 2005;143:486–492
  40. Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721–729
  41. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004;86:28–40
  42. Petersen LR, Roehrig JT. West Nile virus: A reemerging global pathogen. Emerg Infect Dis. 2001;7:611–614
  43. Briese T, Bernard KA. West Nile virus—An old virus learning new tricks. J Neurovirol. 2005;11:469–475
  44. Korves CT, Goldie SJ, Murray MB. Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States. PLoSMed. 2006;3:e21
  45. Korves CT, Goldie SJ, Murray MB. Blood screening for West Nile virus: The cost-effectiveness of a real-time, trigger-based strategy. Clin Infect Dis. 2006;43:490–493
  46. Stramer SL. Reacting to an emerging safety threat: West Nile virus in North America. Dev Biol. 2007;127:43–58
  47. Bernabeu-Wittel M, Ruiz-Perez M, del Toro MD, et al. West Nile virus past infections in the general population of Southern Spain. Enferm Infecc Microbiol Clin. 2007;25:561–565
  48. AuBuchon JP, Littenberg B. A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion. Transfusion. 1996;36:222–226
  49. Hoch JS. Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2004;4:11
  50. Kleinman S, Marshall D, AuBuchon J, et al. Survival after transfusion as assessed in a large multistate US cohort. Transfusion. 2004;44:386–390
  51. Vamvakas EC, Moore SB. Length of survival after perioperative transfusion. Transfus Med. 1997;7:115–121
  52. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion. 1994;34:471–477
  53. Gafni A, Birch S. Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J. 1993;148:913–917
  54. Cleemput I, Leys M, Ramaekers D, et al. Balancing evidence and public opinion in health technology assessments: The case of leukoreduction. Int J Technol Assess Health Care. 2006;22:403–407
  55. Vamvakas EC. Evidence-based practice of transfusion medicine: Is it possible and what do the words mean. Transfus Med Rev. 2004;18:267–278
  56. Robillard P, Nawej KI, Jochem K. The Quebec Hemovigilance System: Description and results from the first two years. Transfus Apheresis Sci. 2004;31:111–122
  57. International Forum: Haemovigilance. Vox Sang. 2006;90:207–241
  58. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: Making decisions about new technologies—Preliminary report of a consensus conference. Vox Sang. 2007;93:179–182
  59. Boucher BA, Hannon TJ. Blood management: A primer for clinicians. Pharmacotherapy. 2007;27:1394–1411

PII: S0887-7963(08)00069-2

doi: 10.1016/j.tmrv.2008.09.001

Transfusion Medicine Reviews
Volume 23, Issue 1 , Pages 1-12 , January 2009

Article Tools

* Image Usage & Resolution